Working… Menu
Trial record 11 of 17 for:    "Adenoma" | "Octreotide"

Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors (LuX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02736500
Recruitment Status : Active, not recruiting
First Posted : April 13, 2016
Last Update Posted : November 9, 2018
Istituto Europeo di Oncologia IEO MILANO
Information provided by (Responsible Party):
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : July 2018
Estimated Study Completion Date : July 2019